Detalhe da pesquisa
1.
Preclinical pharmacology of RA15127343: In vitro and in vivo activity of a novel ultralong-acting basal insulin.
Diabetes Obes Metab
; 24(12): 2411-2419, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892256
2.
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
Diabetes Obes Metab
; 23(1): 166-174, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001554
3.
Long-term stability of insulin glulisine loaded nanoparticles formulated using an amphiphilic cyclodextrin and designed for intestinal delivery.
Drug Dev Ind Pharm
; 46(7): 1073-1079, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32478645
4.
Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.
Diabetologia
; 59(9): 2018-25, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27241182
5.
Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.
Am J Physiol Endocrinol Metab
; 305(12): E1473-82, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24148347
6.
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
J Transl Med
; 11: 84, 2013 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23537041
7.
Erratum to: Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.
Diabetologia
; 60(4): 758-759, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28229179
8.
Revealing the importance of carrier-cargo association in delivery of insulin and lipidated insulin.
J Control Release
; 338: 8-21, 2021 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34298056
9.
Production of a novel heterodimeric two-chain insulin-Fc fusion protein.
Protein Eng Des Sel
; 332020 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159202
10.
Silica-Coated Nanoparticles with a Core of Zinc, l-Arginine, and a Peptide Designed for Oral Delivery.
ACS Appl Mater Interfaces
; 12(1): 1257-1269, 2020 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31802658
11.
Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice.
Front Pharmacol
; 11: 591293, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33679386
12.
SEDDS for intestinal absorption of insulin: Application of Caco-2 and Caco-2/HT29 co-culture monolayers and intra-jejunal instillation in rats.
Int J Pharm
; 560: 377-384, 2019 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30790612
13.
Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin.
J Control Release
; 286: 402-414, 2018 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30075208
14.
Oral delivery of diabetes peptides - Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context.
Adv Drug Deliv Rev
; 106(Pt B): 196-222, 2016 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26964477
15.
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
J Diabetes Complications
; 28(1): 110-4, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-23992745
16.
Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.
Arch Physiol Biochem
; 120(4): 158-65, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25144413
17.
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Expert Opin Drug Discov
; 9(10): 1223-51, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25119443
18.
The metabolic and mitogenic properties of basal insulin analogues.
Arch Physiol Biochem
; 119(1): 1-14, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23373726
19.
Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
Diabetes
; 62(10): 3553-60, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835331
20.
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Regul Pept
; 164(2-3): 58-64, 2010 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20570597